Kinnate Biopharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNTE research report →
Companywww.kinnate.com
Kinnate Biopharma Inc. , a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- CEO
- Nima Farzan
- IPO
- 2020
- Employees
- 84
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $124.99M
- P/E
- -1.10
- P/S
- 0.00
- P/B
- 0.77
- EV/EBITDA
- -0.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.86%
- ROIC
- -73.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-112,649,000 · 1.20%
- EPS
- $-2.42 · 6.56%
- Op Income
- $-119,008,000
- FCF YoY
- -9.04%
Performance & Tape
- 52W High
- $7.18
- 52W Low
- $1.04
- 50D MA
- $2.49
- 200D MA
- $2.25
- Beta
- 1.34
- Avg Volume
- 367.16K
Get TickerSpark's AI analysis on KNTE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 3, 24 | Tananbaum James B. | sell | 40,501 |
| Apr 3, 24 | Tananbaum James B. | sell | 20,250 |
| Apr 3, 24 | Tananbaum James B. | sell | 520,711 |
| Apr 3, 24 | Farzan Nima | sell | 750,000 |
| Apr 3, 24 | Farzan Nima | sell | 275,000 |
| Apr 3, 24 | Farzan Nima | sell | 2,186 |
| Apr 3, 24 | Farzan Nima | sell | 1,281,642 |
| Apr 3, 24 | Farzan Nima | sell | 400,000 |
| Apr 3, 24 | Farzan Nima | sell | 437,413 |
| Apr 3, 24 | MITCHELL DEAN J | sell | 20,250 |
Our KNTE Coverage
We haven't published any research on KNTE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KNTE Report →